Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group - Université Sorbonne Paris Nord Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2017

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group

Domaines

Hématologie

Dates et versions

hal-01653723 , version 1 (01-12-2017)

Identifiants

Citer

Sophie Michallet, Arnaud Campidelli, Helene Lequeu, Marie-Sarah Dilhuydy, Olivier Tournilhac, et al.. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. American Journal of Hematology, 2017, 92 (6), pp.E105 - E107. ⟨10.1002/ajh.24715⟩. ⟨hal-01653723⟩
228 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More